EGFR and non-small cell lung carcinoma: It is reported that up to 20% of EGFRmut NSCLC patients will develop a C797S mutation which confers resistance to first-through-third generation EGFRmut-targeted TKIs by inhibiting their ability to block the ATP-binding pocket of EGFR [49].